Literature DB >> 16078972

Antiaging medicine and mild cognitive impairment: practice and policy issues for geriatrics.

Peter J Whitehouse1, Eric T Juengst.   

Abstract

The claim that aging itself is treatable or even preventable has repeatedly been made over the centuries. Antiaging medicine is the current leader of approaches that even claim that geriatrics as a discipline will become increasingly unnecessary. The concept of mild cognitive impairment (MCI) as a condition intermediate between normal cognitive aging and Alzheimer's disease highlights the conceptual and practical difficulty of differentiating aging from disease. What should geriatricians and their organizations make of scientifically mainstream attempts to decelerate, arrest, or compress aspects of the normal human aging, including the brain aging process? This article reviews the political, philosophical, practice-related, and economical implications of antiaging medicine for geriatrics using MCI as a practical example. It concludes by suggesting actions that geriatricians should consider to strengthen their profession and to improve patient care in response to the challenges of longevity medicine.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  2005        PMID: 16078972     DOI: 10.1111/j.1532-5415.2005.53411.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  6 in total

Review 1.  Involuntary emotional expressive disorder: a case for a deeper neuroethics.

Authors:  Peter J Whitehouse; Sara Waller
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

2.  The evolving classification of dementia: placing the DSM-V in a meaningful historical and cultural context and pondering the future of "Alzheimer's".

Authors:  Daniel R George; Peter J Whitehouse; Jesse Ballenger
Journal:  Cult Med Psychiatry       Date:  2011-09

3.  Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members.

Authors:  J S Roberts; J H Karlawish; W R Uhlmann; R C Petersen; R C Green
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

4.  After the revolution? Ethical and social challenges in 'personalized genomic medicine'

Authors:  Eric T Juengst; Richard A Settersten; Jennifer R Fishman; Michelle L McGowan
Journal:  Per Med       Date:  2012-06-01       Impact factor: 2.512

Review 5.  Mild cognitive impairment: conceptual, assessment, ethical, and social issues.

Authors:  Perla Werner; Amos D Korczyn
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

6.  Ethical issues in early diagnosis and prevention of Alzheimer disease.

Authors:  Peter J Whitehouse
Journal:  Dialogues Clin Neurosci       Date:  2019-03       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.